474 related articles for article (PubMed ID: 24482747)
1. Trial Watch: Lenalidomide-based immunochemotherapy.
Semeraro M; Vacchelli E; Eggermont A; Galon J; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2013 Nov; 2(11):e26494. PubMed ID: 24482747
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
[TBL] [Abstract][Full Text] [Related]
3. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Lacy MQ; Tefferi A
Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
[TBL] [Abstract][Full Text] [Related]
4. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.
Gandhi AK; Kang J; Capone L; Parton A; Wu L; Zhang LH; Mendy D; Lopez-Girona A; Tran T; Sapinoso L; Fang W; Xu S; Hampton G; Bartlett JB; Schafer P
Curr Cancer Drug Targets; 2010 Mar; 10(2):155-67. PubMed ID: 20088798
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide alone and in combination for chronic lymphocytic leukemia.
Chen CI
Curr Hematol Malig Rep; 2013 Mar; 8(1):7-13. PubMed ID: 23254517
[TBL] [Abstract][Full Text] [Related]
6. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
Melchert M; Kale V; List A
Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide in myelodysplastic syndrome and multiple myeloma.
Shah SR; Tran TM
Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955
[TBL] [Abstract][Full Text] [Related]
9. [Review of evidence of thalidomide and lenalidomide in different hematological diseases: chronic lymphocytic leukemia, primary amyloidosis, myelofibrosis and syndrome myelodysplastic].
Jiménez Lozano I; Juárez Jiménez JC
Farm Hosp; 2013; 37(4):322-34. PubMed ID: 24010694
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
Görgün G; Calabrese E; Soydan E; Hideshima T; Perrone G; Bandi M; Cirstea D; Santo L; Hu Y; Tai YT; Nahar S; Mimura N; Fabre C; Raje N; Munshi N; Richardson P; Anderson KC
Blood; 2010 Oct; 116(17):3227-37. PubMed ID: 20651070
[TBL] [Abstract][Full Text] [Related]
11. Molecular action of lenalidomide in lymphocytes and hematologic malignancies.
McDaniel JM; Pinilla-Ibarz J; Epling-Burnette PK
Adv Hematol; 2012; 2012():513702. PubMed ID: 22888354
[TBL] [Abstract][Full Text] [Related]
12. [IMiDs in hematology].
Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
[TBL] [Abstract][Full Text] [Related]
14. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Roziaková L; Mistrík M; Bátorová A
Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
[TBL] [Abstract][Full Text] [Related]
15. The molecular mechanism of thalidomide analogs in hematologic malignancies.
Lindner S; Krönke J
J Mol Med (Berl); 2016 Dec; 94(12):1327-1334. PubMed ID: 27492707
[TBL] [Abstract][Full Text] [Related]
16. The potential of immunomodulatory drugs in the treatment of solid tumors.
Dalgleish A; Galustian C
Future Oncol; 2010 Sep; 6(9):1479-84. PubMed ID: 20919830
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide for the treatment of B-cell malignancies.
Chanan-Khan AA; Cheson BD
J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide: a synthetic compound with an evolving role in cancer management.
Saloura V; Grivas PD
Hematology; 2010 Oct; 15(5):318-31. PubMed ID: 20863427
[TBL] [Abstract][Full Text] [Related]
19. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Palumbo A; Freeman J; Weiss L; Fenaux P
Expert Opin Drug Saf; 2012 Jan; 11(1):107-20. PubMed ID: 22066855
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of lenalidomide in hematological malignancies.
Kotla V; Goel S; Nischal S; Heuck C; Vivek K; Das B; Verma A
J Hematol Oncol; 2009 Aug; 2():36. PubMed ID: 19674465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
